Citi analyst Yigal Nochomovitz lowered the firm’s price target on Lenz Therapeutics (LENZ) to $26 from $52 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- Buy Rating on VIZZ Underscored by Improving Prescription Trends and Long-Term Upside Despite Near-Term Revenue Revisions
- Lenz Therapeutics price target lowered to $29 from $35 at BofA
- Lenz Therapeutics reports Q4 EPS ($1.16), consensus (90c)
- Is LENZ a Buy, Before Earnings?
- Lenz Therapeutics announces submission of MAA to EMA for VIZ